SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is trending as the community rallies around its status as a leading cat-themed meme coin on the Base network, fueling speculation about potential exchange listings and future price breakouts. Investors are actively debating the timing of a rally while comparing current consolidation to previous bullish cycles.

StupidCoin

The StupidCoin community is actively debating the project's legitimacy amidst claims of copycat tokens while sentiment remains bullish on recent chart patterns and potential viral growth. Supporters are framing the asset as a long-term hold, often drawing comparisons to other viral meme coins within the broader Solana ecosystem.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive pre-BLA meeting with the FDA, which confirmed the acceptability of clinical trial data and cleared a path for a potential BLA submission later in 2026. The community is actively discussing the durability and best-in-class potential of their lead candidate, sonelokimab, while debating the significance of upcoming 52-week clinical data and potential M&A activity.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing heightened trading volume and speculative interest as traders debate whether current price action signals a technical breakout or another cycle of retail volatility. The community remains deeply divided, with bulls pointing to the project's data-ownership narrative and potential ecosystem expansion, while bears highlight long-standing skepticism toward leadership and concerns over the token's historical performance relative to broader market momentum.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is generating significant discussion as the community tracks its potential for institutional-led growth, with traders highlighting recent network performance and upcoming integrations as key drivers. Investors are actively debating accumulation strategies near current price levels while monitoring technical breakout points to gauge whether the asset can mirror the historical adoption patterns of other major layer-1 platforms.

Spitcoin is a community-driven cryptocurrency built on the Solana blockchain that powers a decentralized creator economy through the LimitlessFlo platform.  The project focuses on giving creators full control over their content and earnings by enabling instant monetization from day one—through tips, subscriptions, live streaming, and marketplace transactions—without the restrictions of traditional platforms like bans, algorithm suppression, or delayed payouts.  At its core, Spitcoin is about combining meme culture with real utility, creating a self-sustaining ecosystem where platform activity drives token demand, and token usage fuels platform growth.

SpitCoin

SpitCoin is gaining traction as investors highlight its role in the LimitlessFlo ecosystem, with community members actively discussing its strategic partnerships and potential synergy with other trending crypto assets. The project is drawing attention as market participants monitor accumulation activity and express optimism regarding its current developmental momentum.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is currently trending as investors weigh significant concerns over weak quarterly revenue and earnings against the potential for a short squeeze, given the stock's elevated short interest. Community discussion is polarized, with bulls pointing to new management initiatives and potential buyout interest while bears highlight declining foot traffic and broader consumer spending headwinds.

Rewarding holding and rejecting the culture of fast flips. Longterm sustainability by using a multi-phase dynamic rewards system. Meme that inspires creativity and innovation. Fun community involvement, including games, memes, and also serious holder mindset. We have automated rewards to holders, buyback and burns and are giving back to ocean cleanup initiatives. All pump fun creator rewards are used for the buyback and burn of the token, rewarding holders, and donating to nonprofits that clean our oceans.

MAKE HOLDING GREAT AGAIN

MHGA is trending as the community highlights its recent milestones, including verification on major exchange aggregators and the ongoing development of its Solana-based reward mechanism for holders. Investors are actively discussing the project's utility and commitment to charity initiatives while expressing strong conviction in the brand's long-term growth narrative.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around its upcoming one-year anniversary and a significant portion of the supply being locked, fueling sentiment that long-term holders are committed. Investors are highlighting the project's persistent growth and focus on positivity as key drivers for potential upward momentum.

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.

Nurix Therapeutics Inc

Nurix Therapeutics is gaining attention as investors weigh the potential of its targeted protein degradation platform against the challenges of a capital-intensive biotech environment, with the community closely tracking upcoming data readouts and the potential for strategic M&A interest. Supporters emphasize the mechanistic advantages of the company's degrader pipeline, while skeptics remain focused on cash burn and the long-term need for additional funding.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corcept Therapeutics (NASDAQ:CORT) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Corcept Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday...

HC Wainwright Issues Optimistic Outlook for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities research analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for Corcept Therapeutics in a research...

Corcept Therapeutics Incorporated $CORT Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH decreased its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 70.8% in the 4th quarter, according to its most...

Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 7.9%  - Time to Buy?

Corcept Therapeutics (NASDAQ:CORT) Trading 7.9% Higher - Time to Buy...

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Corcept Q1 loss meets estimates, while revenues miss. The company boosts 2026 outlook as new drug Lifyorli and rising Korlym demand reshape growth trajectory.

Corcept Therapeutics (NASDAQ:CORT) Announces Earnings Results

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of...

Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates

Corcept (CORT) delivered earnings and revenue surprises of -1.11% and -4.37%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics Q1 Earnings Call Highlights

Corcept Therapeutics (NASDAQ:CORT) reported first-quarter 2026 revenue of $164.9 million, up from $157.2 million in the prior-year period, and raised its full-year 2026 revenue guidance to a range of $950 million to $1.05 billion. The company also reported a net loss of $31.8 million for the quarter...

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.01	--	--	N/A
Q1 '26	-$0.11	-$0.30	-176.52%	MISSED
Q4 '25	$0.33	$0.20	-39.30%	MISSED
Q3 '25	$0.13	$0.16	18.98%	BEAT
Q2 '25	$0.19	$0.29	54.67%	BEAT

CORT
Corcept Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest CORT News

CORTCorcept Therapeutics Inc